Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease
- PMID: 24980270
- DOI: 10.1111/apt.12833
Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease
Abstract
Background: The safety of anti-tumour necrosis factor (TNF) agents during pregnancy is a major concern for child-bearing women and physicians.
Aim: To assess the impact of anti-TNF therapy on adverse pregnancy and foetal outcomes in women with inflammatory bowel disease (IBD).
Methods: Pregnancies occurring during anti-TNF treatment or less than 3 months after its cessation in IBD patients followed in GETAID centres were recorded from January 2009 to December 2010. Ninety-nine pregnancies in women without anti-TNF treatment were identified from the CESAME registry. We compared pregnancy and neonatal outcomes by a case-control study.
Results: In the 124 IBD patients followed, 133 pregnancies were reported. At the conception time, 23% of patients had active disease. Eighty-eight per cent (n = 117) of the 133 pregnancies followed until delivery resulted in 118 liveborns (one twin pregnancy). Complications were observed in 47 (35%) women and 24 (20%) newborns. In multivariate analysis, factors associated with pregnancy complications were: current smoking (P = 0.004), a B2 (stenotic) phenotype in CD women (P = 0.004), occurrence of a flare during pregnancy (P = 0.006) and a past history of complicated pregnancy (P = 0.007). Current smoking was the only factor associated with severe (i.e. potentially lethal) pregnancy complications (P = 0.02). Having IBD for more than 10 years prior to conception was associated with newborn complications (P = 0.007). No difference was found with the control group for any of the pregnancy and neonatal outcomes.
Conclusion: In our series, the safety profile of anti-TNF therapy during pregnancy and the neonatal period appears similar to control group of IBD women not treated with anti-TNF therapy.
© 2014 John Wiley & Sons Ltd.
Similar articles
-
Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study.Aliment Pharmacol Ther. 2020 Jan;51(1):129-138. doi: 10.1111/apt.15539. Epub 2019 Nov 6. Aliment Pharmacol Ther. 2020. PMID: 31692017
-
Anti-Tumour Necrosis Factor α Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis.J Crohns Colitis. 2016 Aug;10(8):979-88. doi: 10.1093/ecco-jcc/jjv234. Epub 2016 Jan 11. J Crohns Colitis. 2016. PMID: 26755733 Review.
-
Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety.Gut. 2016 Aug;65(8):1261-8. doi: 10.1136/gutjnl-2015-309321. Epub 2015 May 12. Gut. 2016. PMID: 25966992
-
Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.Am J Gastroenterol. 2013 Mar;108(3):433-40. doi: 10.1038/ajg.2012.430. Epub 2013 Jan 15. Am J Gastroenterol. 2013. PMID: 23318480
-
Anti-TNF antibody therapy for inflammatory bowel disease during pregnancy: a clinical review.Curr Drug Targets. 2010 Feb;11(2):234-41. doi: 10.2174/138945010790309885. Curr Drug Targets. 2010. PMID: 19916950 Review.
Cited by
-
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review.BMC Pregnancy Childbirth. 2024 Apr 8;24(1):251. doi: 10.1186/s12884-024-06443-w. BMC Pregnancy Childbirth. 2024. PMID: 38589784 Free PMC article.
-
IBD and Motherhood: A Journey through Conception, Pregnancy and Beyond.J Clin Med. 2023 Sep 25;12(19):6192. doi: 10.3390/jcm12196192. J Clin Med. 2023. PMID: 37834837 Free PMC article. Review.
-
Decreased Risk of Preeclampsia in Women with Inflammatory Bowel Disease on Anti-Tumor Necrosis Factor Therapy.Dig Dis Sci. 2023 Sep;68(9):3557-3561. doi: 10.1007/s10620-023-08016-x. Epub 2023 Jul 5. Dig Dis Sci. 2023. PMID: 37402980
-
Inflammatory bowel disease in pregnancy and breastfeeding.Nat Rev Gastroenterol Hepatol. 2023 Aug;20(8):504-523. doi: 10.1038/s41575-023-00758-3. Epub 2023 Mar 31. Nat Rev Gastroenterol Hepatol. 2023. PMID: 37002407 Review.
-
Pregnancy in Patients with Inflammatory Bowel Diseases-A Literature Review.Life (Basel). 2023 Feb 9;13(2):475. doi: 10.3390/life13020475. Life (Basel). 2023. PMID: 36836832 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous